STOCK TITAN

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that its CEO, John Quisel, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:30 p.m. ET. The event aims to highlight the company's innovative treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis.

The fireside chat will be accessible via a live webcast on the investor relations section of the company's website, with an archived replay available post-event. Disc Medicine is dedicated to developing novel therapies targeting fundamental biological pathways in hematologic diseases.

Positive
  • None.
Negative
  • None.

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 2:30 p.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com

Investor Relations Contact

Suzanne Messere
Stern Investor Relations
suzanne.messere@sternir.com


FAQ

When is the H.C. Wainwright BioConnect Investor Conference where IRON will participate?

The H.C. Wainwright BioConnect Investor Conference is on May 2, 2023, at 2:30 p.m. ET.

Who will represent IRON at the H.C. Wainwright BioConnect Investor Conference?

John Quisel, the CEO of Disc Medicine, will represent IRON at the conference.

How can I watch the IRON fireside chat at the conference?

The fireside chat will be available via a live webcast on the investor relations section of Disc Medicine's website.

What is the focus of Disc Medicine and its therapies?

Disc Medicine focuses on developing treatments for serious hematologic diseases by addressing red blood cell biology and iron homeostasis.

Where can I find more information about Disc Medicine?

More information about Disc Medicine can be found at www.discmedicine.com.

Disc Medicine, Inc.

NASDAQ:IRON

IRON Rankings

IRON Latest News

IRON Stock Data

1.43B
29.73M
12.55%
98.53%
4.58%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WATERTOWN